Oral Micronized Progesterone and Tadalafil Interaction

Why This Combination Comes Up in Clinical Practice

Women on hormone replacement therapy (HRT) who take oral micronized progesterone for endometrial protection sometimes also receive tadalafil for conditions including female sexual dysfunction research protocols, Raynaud phenomenon, or pulmonary arterial hypertension. Men on progesterone for specific off-label indications (prostate-related or sleep) may concurrently use tadalafil for erectile dysfunction (ED) or benign prostatic hyperplasia (BPH).

The FDA-approved labeling for Prometrium lists CYP3A4 as a major metabolic pathway for progesterone [1]. Tadalafil's label similarly identifies CYP3A4 as the principal enzyme responsible for its biotransformation [2]. When two drugs share the same cytochrome P450 isoform, clinicians rightly ask whether co-administration alters exposure for either agent. The answer here is reassuring. Neither oral micronized progesterone nor tadalafil acts as a strong inhibitor or inducer of CYP3A4, so competitive substrate inhibition at therapeutic concentrations is minimal [3]. Drug-drug interaction (DDI) databases including Lexicomp and Clinical Pharmacology rate this pairing as low severity [4].

Pharmacokinetic Overlap: CYP3A4 Substrate Competition

Both drugs are metabolized by CYP3A4, but the clinical significance of that overlap is small. Progesterone undergoes extensive first-pass hepatic metabolism. Its oral bioavailability is only about 10% in the micronized formulation, with the majority of clearance occurring through CYP3A4 and, to a lesser extent, CYP2C19 [1]. Tadalafil, by contrast, has roughly 36% oral bioavailability and is predominantly cleared by CYP3A4 with a terminal half-life of 17.5 hours [2].

A true interaction would require one drug to meaningfully inhibit or induce the enzyme while the other is being cleared. Strong CYP3A4 inhibitors such as ketoconazole increase tadalafil AUC by 312% according to the Cialis prescribing information [2]. Progesterone does not produce this effect. In vitro data show progesterone has weak, concentration-dependent inhibitory activity on CYP3A4 at supraphysiologic concentrations, but at the 100 to 200 mg oral doses used clinically, circulating progesterone levels (peak ~17 to 38 ng/mL after 200 mg) are far below the Ki for meaningful enzyme inhibition [5].

The reverse scenario (tadalafil affecting progesterone levels) is also negligible. Tadalafil is not listed as a CYP3A4 inhibitor in its FDA label, and no published pharmacokinetic studies report altered progesterone exposure during co-administration [2].

Pharmacodynamic Considerations: Blood Pressure and Sedation

The more relevant clinical concern is pharmacodynamic. Tadalafil reduces systemic blood pressure by a mean of 1.6/0.8 mmHg at the 20 mg dose, according to pooled data from registration trials [2]. In the IIEF studies (N=1,112), dizziness occurred in approximately 2% of tadalafil-treated patients versus 1% on placebo [6]. Progesterone and its neuroactive metabolite allopregnanolone produce vasodilatory effects through endothelium-dependent nitric oxide pathways, though the magnitude is modest at HRT doses [7]. A 2003 study by Rosano et al. (N=18 postmenopausal women) demonstrated that oral micronized progesterone 200 mg reduced 24-hour ambulatory systolic blood pressure by 4 mmHg compared to medroxyprogesterone acetate [8].

When combined, these effects can be additive. Patients with baseline systolic blood pressure below 110 mmHg or those taking antihypertensive medications concurrently warrant closer monitoring. Orthostatic symptoms (lightheadedness on standing) are the most likely clinical manifestation.

Sedation is the other overlap. Progesterone's conversion to allopregnanolone, a positive allosteric modulator of GABA-A receptors, produces dose-dependent drowsiness [1]. The Prometrium label recommends bedtime dosing specifically because of this effect. Tadalafil does not cause CNS depression, but its low-grade dizziness combined with progesterone's sedation could produce subjective unsteadiness in sensitive individuals.

Severity Rating and DDI Database Classification

Major DDI databases classify this pairing below the threshold that triggers automatic alerts in most electronic health record systems. Lexicomp rates the interaction as "C: Monitor therapy," meaning the combination can be used with appropriate clinical surveillance [4]. This contrasts sharply with the "X: Avoid combination" rating assigned to tadalafil plus organic nitrates (nitroglycerin, isosorbide mononitrate), where co-administration can produce life-threatening hypotension [2].

The distinction matters because progesterone is sometimes loosely grouped with "hormones that affect vascular tone." It is not a nitric oxide donor. It does not activate soluble guanylate cyclase. The mechanism by which nitrates produce catastrophic hypotension with PDE5 inhibitors (massive cGMP accumulation in vascular smooth muscle) does not apply to progesterone [9]. Dr. Robert Kloner, a cardiologist who authored the original ACC/AHA consensus on PDE5 inhibitor cardiovascular safety, stated: "The nitrate contraindication is specific to agents that directly donate nitric oxide or stimulate cGMP production. Hormonal agents that mildly lower blood pressure through other mechanisms do not carry the same absolute risk" [10].

Dose Adjustment: When Is It Needed?

For the majority of patients, no dose adjustment is required. Standard dosing protocols for both drugs can proceed unchanged.

Consider reducing the tadalafil dose from 20 mg to 10 mg as-needed (or from 5 mg to 2.5 mg daily) in patients who meet all three of the following criteria: baseline systolic blood pressure consistently below 110 mmHg, concurrent use of another antihypertensive agent, and a history of orthostatic intolerance. This recommendation aligns with the general tadalafil label guidance for patients on multiple vasodilators [2].

Progesterone dosing should remain at the standard 200 mg at bedtime (cyclic) or 100 mg daily (continuous) as recommended by the 2022 North American Menopause Society (NAMS) position statement for endometrial protection [11]. Reducing the progesterone dose to accommodate tadalafil would compromise endometrial safety and is not warranted by the interaction profile.

The 2017 Endocrine Society Clinical Practice Guideline for testosterone therapy in men notes that progesterone is occasionally used off-label in male patients; if tadalafil is co-prescribed in this context, the same blood-pressure monitoring approach applies [12].

Monitoring Protocol for Co-Prescribed Patients

A structured monitoring approach reduces risk without requiring specialty referral.

At initiation, measure seated blood pressure and heart rate before the first co-administration. Patients already stable on one drug can add the second and recheck blood pressure at 1 hour post-dose on the first day (particularly relevant for as-needed tadalafil dosing).

At the 2-week mark, reassess blood pressure during a routine follow-up or via home monitoring. Ask specifically about lightheadedness when standing, morning dizziness (given that progesterone is dosed at bedtime), and any syncopal or pre-syncopal episodes.

Ongoing monitoring should include blood pressure checks at standard HRT follow-up intervals (every 3 to 6 months per NAMS guidance) [11]. If the patient is on daily tadalafil 5 mg for BPH, renal function monitoring (eGFR) should follow the tadalafil label recommendation of annual assessment in patients over 65 [2].

Other Progesterone Drug Interactions to Know

Oral micronized progesterone has a broader interaction profile beyond tadalafil that prescribers should keep in view.

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) increase progesterone exposure. The Prometrium label warns that co-administration with ketoconazole "may increase the bioavailability of progesterone" [1]. No specific AUC multiplier is provided in the label, but by analogy to other CYP3A4 substrates, a 2- to 4-fold increase is plausible.

Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) reduce progesterone levels and could compromise endometrial protection. A 2019 pharmacokinetic study by Marjoribanks et al. in the Cochrane Database noted that enzyme-inducing antiepileptic drugs may reduce the efficacy of progestogens used in HRT [13].

Alcohol amplifies progesterone's sedative effects. The Prometrium label recommends avoiding alcohol within 2 hours of dosing [1]. This is clinically relevant because tadalafil's dizziness can compound the impairment.

The 2020 American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on hormone therapy states: "Clinicians should review the full medication list before initiating HRT, with particular attention to CYP3A4 inhibitors and inducers that may alter progestogen exposure" [14].

Special Populations

Hepatic impairment changes the calculus. Progesterone is contraindicated in patients with severe hepatic dysfunction because first-pass metabolism is impaired and allopregnanolone accumulation increases CNS depression risk [1]. Tadalafil exposure (AUC) in patients with Child-Pugh Class B cirrhosis is comparable to healthy controls for the 10 mg dose, but the 20 mg dose has not been studied in this population [2]. In patients with mild-to-moderate hepatic impairment on both drugs, start tadalafil at the lowest effective dose.

Renal impairment does not meaningfully alter progesterone pharmacokinetics, as hepatic metabolism dominates. For tadalafil, the FDA label recommends a maximum of 5 mg daily in patients with creatinine clearance 30 to 50 mL/min and avoidance in patients on hemodialysis taking as-needed dosing [2].

Older adults (over 65) metabolize both drugs more slowly. Progesterone's sedative metabolite allopregnanolone may accumulate to a greater degree, and tadalafil's half-life extends modestly. Combined orthostatic risk is highest in this group, particularly in patients on alpha-blockers for BPH. The 2023 Beers Criteria from the American Geriatrics Society flag PDE5 inhibitors combined with alpha-blockers as a concern; adding progesterone's mild vasodilatory effect to that combination warrants heightened vigilance [15].

Patient Counseling Points

Prescribers and pharmacists should cover five specific points when a patient will take both drugs.

First, take progesterone at bedtime as directed. Its sedative effect peaks 1 to 3 hours post-dose [1]. If tadalafil is used as-needed, taking it earlier in the evening (rather than at bedtime) separates the peak drug effects and reduces additive dizziness.

Second, avoid alcohol on nights when both drugs are taken. The triple combination of progesterone-induced sedation, tadalafil-related dizziness, and alcohol impairment creates meaningful fall risk.

Third, rise slowly from sitting or lying positions, especially during the first week of co-administration. Orthostatic hypotension is most likely before cardiovascular adaptation occurs.

Fourth, the combination is not the same as taking a nitrate with tadalafil. Patients should not stop either medication out of concern for the nitrate interaction, which does not apply here.

Fifth, report sustained dizziness, fainting, or blood pressure readings below 90/60 mmHg. These warrant dose reassessment.